Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) involve a complex interplay of genetics, metabolism, and the gut-liver axis. In a new study, Zhang et al. assess a previously unrecognized role of the intestinal epithelium in protecting against MASH by focusing on Transmembrane 6 Superfamily Member 2 (TM6SF2), a gene highly expressed in both the liver and intestine, whose common loss-of-function variant (E167K) is a well-established genetic risk factor for MASLD/MASH in humans. Herein, we provide an overview of Zhang et al.’s study and highlight the clinical significance of these new findings by focusing on two specific areas: the gut-liver axis in MASLD and the modification of the intestinal microbiota.

Keywords

TM6SF2 / E167K / microbiome / gut-liver axis / LPA pathway

References

[1] Younossi ZM,Henry L.Epidemiology of metabolic dysfunction-associated steatotic liver disease.Clin Mol Hepatol2025;31:S32-50 PMCID:PMC11925440

[2] Kozlitina J,Stender S.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2014;46:352-6 PMCID:PMC3969786

[3] Mahdessian H,Popov S.TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.Proc Natl Acad Sci U S A2014;111:8913-8 PMCID:PMC4066487

[4] Zhang X,Ha S.Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis.Nat Metab2025;7:102-19 PMCID:PMC11774752

[5] Knowlden S.The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.J Immunol2014;192:851-7 PMCID:PMC3905607

[6] Dongiovanni P,Maglio C.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology2015;61:506-14

[7] De Munck TJI,Verwijs HJA.Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis.Liver Int2020;40:2906-16 PMCID:PMC7756870

[8] Henao-Mejia J,Jin C.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.Nature2012;482:179-85 PMCID:PMC3276682

[9] Sakuma I,Luukkonen PK.Lysophosphatidic acid triggers inflammation in the liver and white adipose tissue in rat models of 1-acyl-sn-glycerol-3-phosphate acyltransferase 2 deficiency and overnutrition.Proc Natl Acad Sci U S A2023;120:e2312666120 PMCID:PMC10756285

[10] Del Barrio M,Santos-Laso Á.Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease.Int J Mol Sci2023;24:6123 PMCID:PMC10094628

[11] Wang Q,Jin Y.Applications of human organoids in the personalized treatment for digestive diseases.Signal Transduct Target Ther2022;7:336 PMCID:PMC9513303

[12] Gill MW,Cheng PTW,Davis M.Mechanism of hepatobiliary toxicity of the LPA₁ antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278.Toxicol Appl Pharmacol2022;438:115885

[13] Giardoglou P,Amanatidou AI.Development of a polygenic risk score for metabolic dysfunction-associated steatotic liver disease prediction in UK biobank.Genes2024;16:33 PMCID:PMC11765347